In various malignancies, including GC, the expression of EGLN3, which belongs to the EGL-9 family of hypoxia-inducible factors, has been reported to be significantly downregulated in a study by Cai et al. This reduction in EGLN3 expression in GC tissues correlates with poorer patient prognosis, suggesting its potential role as a prognostic biomarker. The gene discussed is EGLN3; the disease is gastric cancer.